Benzocaine studies
This article was originally published in The Tan Sheet
Executive Summary
A retrospective analysis of the dose-response relationship between 10% and 20% strengths of benzocaine "does not adequately support the dose response" of drug, FDA says in Oct. 29 letter responding to CHPA data submission (1"The Tan Sheet" July 8, 2002, p. 15). Agency reiterates call for one efficacy study to evaluate both 10%, 20% benzocaine compared with placebo for toothache. In addition, FDA advises study labeling must include language that directs consumer to seek treatment if relief is not obtained after several doses. Finally, agency requests updated assessment of methemoglobinemia cases associated with benzocaine use...
You may also be interested in...
Benzocaine Dose-Response Seen Strongest In Severe Toothache Pain – CHPA
The dose-response relationship of 10% and 20% strengths of benzocaine is particularly significant for patients with severe toothache pain, data forwarded to FDA by the Consumer Healthcare Products Association suggests
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.